News | June 21, 2025
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
CRL shall invest another Rs. 200 crore for creation of additional beds
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Subscribe To Our Newsletter & Stay Updated
